Among the most promising tools of cancer therapy, engineered immune cells known as chimeric antigen-receptor (CAR) T cells ...
In 2024, Professor Sebastian Kobold's research group at LMU University Hospital had already shown that the metabolite ...
Carfilzomib prevented BCMA degradation, increased target density, and improved CAR T susceptibility by ~26%–28% in vitro, while enhancing xenograft antitumor activity without worsening T-cell ...
In the rapidly moving field, questions remain regarding long-term safety, durability of remission, and the FDA’s approach to ...
In a phase 1 study, anti-CD7 chimeric antigen receptor (CAR) T cells induced complete remission in children and adults with relapsed or refractory T-cell acute lymphoblastic leukemia (ALL), with 82% ...
The Chosun Ilbo on MSN
In vivo CAR-T offers single-shot cancer treatment
A method called "in vivo CAR-T (in vivo CAR-T·intra-body CAR-T)" that directly alters immune cells within the body with a single injection is recently changing the landscape of the cancer treatment ...
Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of life science research, ...
CAR T-cell therapy, which transforms patients’ own immune cells into cancer-fighting warriors, has revolutionized how physicians treat cancer, especially blood cancers. “These patients can be cured ...
RNA CAR T therapy Descartes‑08 targets BCMA‑positive plasma cells and delivers year‑long symptom relief in myasthenia gravis after a brief course, signaling a new era of durable treatment.
CAR T-cell therapy was first developed as a lymphoma treatment but has recently been applied to autoimmune diseases, primarily lupus, systemic sclerosis, and myositis. Up to this point, ulcerative ...
Jefferson Health oncologist Jennifer Johnson had exhausted all the standard treatment options for her 49-year-old patient ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results